<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26044830</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>12</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2568</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>60</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2015</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Digestive diseases and sciences</Title>
<ISOAbbreviation>Dig. Dis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.</ArticleTitle>
<Pagination>
<MedlinePgn>3075-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-015-3735-4</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The outcomes of infliximab dose escalation in ulcerative colitis (UC) have not been well evaluated.</AbstractText>
<AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess the short- and long-term outcomes of infliximab dose escalation in a cohort of patients with UC.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This was a multicenter, retrospective, cohort study. All consecutive UC patients who had lost response to infliximab maintenance infusions and who underwent infliximab dose escalation were included. Post-escalation short-term clinical response and remission were evaluated. In the long term, the cumulative probabilities of infliximab failure-free survival and colectomy-free survival were calculated. Predictors of short-term response and event-free survival were estimated using logistic regression analysis and Cox proportional hazard regression analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-nine patients were included. Fifty-four patients (68.4%) achieved short-term clinical response and 41 patients (51.9%) entered in clinical remission. After a median follow-up of 15 months [interquartile range (IQR) 8-26], 33 patients (41.8%) had infliximab failure. Patients with short-term response had a significantly lower adjusted rate of infliximab failure [hazard ratio (HR) 0.24, 95% confidence interval (CI) 0.12-0.49; p &lt; 0.001]. During a median follow-up of 24 months (IQR 13-34), 9 patients (11.4%) needed colectomy. Short-term response was identified as a predictor of colectomy avoidance (HR 0.14; 95% CI 0.03-0.69; p &lt; 0.007).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In UC patients who lost response to infliximab during maintenance, infliximab dose escalation enabled recovery of short-term response in nearly 70% of patients. In the long term, 58% of patients maintained sustained clinical benefit, and 9 of 10 avoided colectomy. Short-term response was associated with an 86% reduction in the relative risk of colectomy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Taxonera</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040, Madrid, Spain. carlos.taxonera@salud.madrid.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. carlos.taxonera@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barreiro-de Acosta</LastName>
<ForeName>Manuel</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Clínico de Santiago, Santiago de Compostela, Spain. manubarreiro@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Calvo</LastName>
<ForeName>Marta</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Puerta de Hierro, Madrid, Spain. calvo.marta@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Saro</LastName>
<ForeName>Cristina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital de Cabueñes, Gijón, Spain. csarog@telefonica.net.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bastida</LastName>
<ForeName>Guillermo</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital La Fe, Valencia, Spain. guille.bastida@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martín-Arranz</LastName>
<ForeName>María D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital La Paz, Madrid, Spain. mmartinarranz@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gisbert</LastName>
<ForeName>Javier P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain. javier.p.gisbert@gmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. javier.p.gisbert@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>García-Sánchez</LastName>
<ForeName>Valle</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Reina Sofía and IMIBIC, Universidad de Córdoba, Córdoba, Spain. vallegarciasanchez@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marín-Jiménez</LastName>
<ForeName>Ignacio</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Gregorio Marañón, Madrid, Spain. drnachomarin@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bermejo</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital de Fuenlabrada, Madrid, Spain. fbermejo.hflr@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chaparro</LastName>
<ForeName>María</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain. mariachs2005@gmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. mariachs2005@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ponferrada</LastName>
<ForeName>Ángel</ForeName>
<Initials>Á</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Infanta Leonor, Madrid, Spain. angelponmedicina@yahoo.es.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Martínez-Montiel</LastName>
<ForeName>María P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital 12 de Octubre, Madrid, Spain. pilarmarmon123@telefonica.net.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pajares</LastName>
<ForeName>Ramón</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Infanta Sofía, Madrid, Spain. rpajaresvi@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Gracia</LastName>
<ForeName>Celia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Gastroenterology, Hospital Gregorio Marañón, Madrid, Spain. celiadgf@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Olivares</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040, Madrid, Spain. david.olivares@salud.madrid.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. david.olivares@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Alba</LastName>
<ForeName>Cristina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040, Madrid, Spain. cristina.alba@telefonica.net.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. cristina.alba@telefonica.net.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mendoza</LastName>
<ForeName>Juan L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo>
<Affiliation>Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040, Madrid, Spain. juanluis.mendoza@salud.madrid.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. juanluis.mendoza@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fernández-Blanco</LastName>
<ForeName>Ignacio</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>Inflammatory Bowel Disease Unit, Hospital Universitario Moncloa, Madrid, Spain. fernandezblanco@telefonica.net.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D023362">Evaluation Studies</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>06</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Dig Dis Sci</MedlineTA>
<NlmUniqueID>7902782</NlmUniqueID>
<ISSNLinking>0163-2116</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>B72HH48FLU</RegistryNumber>
<NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003082">Colectomy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003093">Colitis, Ulcerative</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016001">Confidence Intervals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005765">Gastrointestinal Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069285">Infliximab</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cohort study</Keyword>
<Keyword MajorTopicYN="N">Colectomy</Keyword>
<Keyword MajorTopicYN="N">Dose escalation</Keyword>
<Keyword MajorTopicYN="N">Dose optimization</Keyword>
<Keyword MajorTopicYN="N">Infliximab</Keyword>
<Keyword MajorTopicYN="N">Ulcerative colitis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>03</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>05</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>12</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26044830</ArticleId>
<ArticleId IdType="doi">10.1007/s10620-015-3735-4</ArticleId>
<ArticleId IdType="pii">10.1007/s10620-015-3735-4</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Crohns Colitis. 2010 Oct;4(4):355-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21122530</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aliment Pharmacol Ther. 2012 Oct;36(7):650-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22860894</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2014 Feb;146(2):392-400.e3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24512909</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Gastroenterol. 2014 Apr 23;14:80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24758588</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16151544</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Crohns Colitis. 2008 Sep;2(3):219-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21172214</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aliment Pharmacol Ther. 2011 Feb;33(3):340-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21133961</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2013 Aug 22;369(8):699-710</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23964932</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2004 Feb;126(2):402-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14762776</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2015 Jun;21(6):1359-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25989340</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Gastroenterol. 2015 Sep;49(8):675-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25389599</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Dec 8;353(23):2462-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16339095</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastroenterol. 2014 Jul 21;20(27):9170-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25083091</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2009 Mar;104(3):760-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19174781</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2012 Feb;18(2):201-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21484965</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Gastroenterol Hepatol. 2015 Mar;13(3):531-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25117777</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2013 Nov;19(12):2568-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24013361</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19596014</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Immunol. 2014 Jan;75(1):71-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24121042</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2010 Dec;105(12):2617-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20736936</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Dig Liver Dis. 2014 Feb;46(2):135-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24246151</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Drug Targets. 2011 Sep;12(10):1440-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21466486</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aliment Pharmacol Ther. 2012 Mar;35(5):562-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22239070</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Crohns Colitis. 2014 Oct;8(10):1331-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24690137</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gut. 2010 Jan;59(1):49-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19651627</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21045814</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2012 Nov;18(11):2026-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22294554</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2012 Feb;142(2):257-65.e1-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22062358</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2014 Jan;146(1):96-109.e1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23770005</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>